High Sensitivity Intact Monoclonal Antibody (mAb) HRMS Quantification

Importance of the Topic

Monoclonal antibodies (mAbs) such as trastuzumab represent a cornerstone in modern biotherapeutics. Their high molecular weight, structural complexity, and microheterogeneity demand analytical strategies capable of sensitive and accurate intact protein quantification. Traditional ligand-binding assays or peptide surrogate methods offer indirect measurements and require extensive sample preparation. High-resolution mass spectrometry (HRMS) for direct intact protein quantification presents a powerful alternative by preserving isoform information and simplifying workflows.

Objectives and Study Overview

This study aims to develop and evaluate an HRMS-based liquid chromatography method for highly sensitive intact quantification of trastuzumab spiked into bovine serum albumin (BSA) matrix. Key goals include:

• Achieve a lower limit of quantification (LLOQ) of ≤3 ng/mL (30 pg on column).
• Establish linear dynamic range, accuracy, and reproducibility according to bioanalytical standards.
• Optimize data processing parameters such as mass tolerance window and peak summation strategy.

Methodology and Instrumentation

The workflow combines ultra-performance liquid chromatography (UPLC) separation with full-scan electrospray ionization HRMS detection and specialized data processing.

• Chromatography: Waters ACQUITY UPLC I-Class system, polystyrene divinylbenzene column (3×50 mm, 4 µm, 1500 Å), 0.2 mL/min gradient from 2 % to 90 % acetonitrile (0.1 % formic acid), 80 °C column temperature.
• Mass Spectrometry: Waters Vion IMS QTof, ESI+ mode, m/z 500–4000 full scan, sensitivity mode, capillary voltage 2.75 kV, cone voltage 150 V, desolvation gas 800 L/h at 600 °C.
• Sample Preparation: Serial dilution of trastuzumab (20 mg/mL stock) into 0.1 mg/mL BSA in 0.1 % formic acid across 3 ng/mL to 100 µg/mL range; triplicate injections.
• Data Processing: Waters UNIFI Scientific Information System (v1.8.2) using the Quantify Assay 2D Tof method. Variables assessed include mass tolerance windows (0.1–2.0 Da and a wide 1000 Da) and summation of different numbers of charge-state peaks (1 to 42 peaks).

Main Results and Discussion

Under optimized conditions trastuzumab elutes at 4.6 min with baseline separation from BSA. The m/z envelope spans 2000–3500 with multiple charge states (≈52+–55+) and glycoform peaks. Key findings include:

• LLOQ of 3 ng/mL (S/N ≥10) achieved using a 0.5–1.0 Da mass tolerance window and summation of top 6–9 most abundant glycoform peaks.
• Linear dynamic range from 3 ng/mL to 780 ng/mL (R² = 0.98, 1/X² weighting) and up to 1560 ng/mL in log-log scale (R² = 0.997).
• Reproducibility (%RSD) at LLOQ: best performance (≤5 %) with 0.5–1.0 Da window and summation of 6–9 peaks; single peak or very wide window yielded high RSDs (>20 %).
• Mass tolerance optimization balances selectivity and sensitivity—very narrow windows (<0.1 Da) reduce signal coverage, very wide windows (>2 Da) increase noise.

Benefits and Practical Applications

This intact-level HRMS approach offers:

• Direct measurement of full antibody mass and isoform distribution without digestion.
• High sensitivity comparable to immunoassays but with simplified sample prep.
• Flexible data processing to tailor sensitivity and precision for various matrices.
• Complementarity to surrogate peptide LC-MS/MS and ligand binding assays in bioanalysis, QA/QC, and bioprocess monitoring.

Future Trends and Applications

As biotherapeutic portfolios expand, direct intact quantification will benefit from:

• Integration of ion mobility separation to resolve isoforms and charge variants.
• Advanced deconvolution algorithms for rapid spectral interpretation.
• Automated, software-driven parameter optimization for diverse proteins and complex matrices.
• Adoption in regulatory bioanalysis for PK/PD studies and biosimilarity assessments.

Conclusion

This work demonstrates that HRMS can achieve highly sensitive and reproducible intact quantification of a 150 kDa monoclonal antibody in a protein matrix. Optimizing mass tolerance and peak summation is critical for reliable LLOQ performance. The described method provides a streamlined, direct-analysis alternative to traditional antibody bioanalysis techniques.

References

1. Waters Corporation. High Sensitivity Intact Monoclonal Antibody (mAb) HRMS Quantification. Application Note, 2018.